RxVantage
4 known investors
Platform connecting healthcare providers with life science experts to access critical information and insights.
Also known as RxV · RxVantage, Inc.
Investors · 4
Company profile
researched Aug 2026RxVantage operates a software and data platform that connects healthcare professionals and medical practices with life science companies and their representatives. The core product is an application that lets practices schedule and manage meetings with reps, communicate with them directly, and access educational resources such as information on medications, treatment protocols and patient assistance programs. Practices control which representatives can access which clinical areas, and engagements are increasingly conducted virtually through the platform.
The company was established in 2008 and is headquartered in El Segundo, California. Founders cited include Greg Gilman, James Dwyer and Jeremy Gilman; Dan Gilman is identified as founder and CEO. Its industry classifications include healthcare IT, education and training services, communication and conferencing software, and web applications, with cloud, edtech and mobile app verticals.
Founding story
Established in 2008 by founders identified as Greg Gilman, James Dwyer and Jeremy Gilman, who had previously started other ventures; Dan Gilman is identified as founder and CEO.
Business model
RxVantage sells platform access to medical practices on a subscription basis, billed annually or monthly, covering meeting scheduling, direct communication with life science representatives, and a resource library including patient assistance programs. The model is complemented by direct partnerships with life science companies, which add supply of experts and resources to the network.
Subscription fees from healthcare practices for platform access, supplemented by partnerships with life science companies.
Traction
As of the January 2022 investment announcement, the company reported adding more than 2,500 leading medical practices to its network, more than 55,000 active life science experts, over 70 direct partnerships with life sciences companies, a 100 percent customer renewal rate, and more than 100 employees added during 2021, both organically and through the acquisition of onPoint oncology. A separate profile cites over 16,000 medical practices and 100,000 life science experts on the platform.
Latest developments
In January 2022 RxVantage announced a funding round led by Spectrum Equity and McKesson Ventures, joining existing investors dRx Capital, Merck Global Health Innovation Fund, Javelin Venture Partners and Slater Technology Fund. Proceeds were earmarked for adding practices to the network, product innovation and further team growth, with stated plans to more than double headcount and to enter European and Asian markets by 2025.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Positioned at the intersection of digital health and data analytics, with a network reported at over 16,000 medical practices and 100,000 life science experts, and characterized by an investor as having scaled quickly with a 100 percent customer renewal rate.
The platform takes a "provider-first" approach, giving practices transparency and control over which representatives may access specific clinical areas, so that interactions remain relevant to patient care rather than being driven by rep outreach.
Technology
An application-based platform enabling secure scheduling, instant messaging and virtual engagement between healthcare professionals and life science experts, plus a resource library; data analytics capabilities were cited as an area for further development.
Go-to-market
Direct subscription sales to medical practices combined with direct partnerships with life science companies that bring their representatives and educational resources onto the platform.
Medical practices and healthcare professionals in the United States and select international markets, together with life science companies and their field representatives.
Geography
Headquartered in El Segundo, California, serving customers primarily in the United States and select international markets, with stated plans to expand into Europe and Asia by 2025.
History
Founded in 2008 and based in El Segundo, California, RxVantage raised early institutional capital including a $2 million Series A led by Javelin Venture Partners, with investors that came to include Slater Technology Fund, dRx Capital (Novartis), Merck Global Health Innovation Fund and Wavemaker Partners. In 2021 the company acquired onPoint oncology and expanded headcount by more than 100. In January 2022 it announced a growth investment led by Spectrum Equity and McKesson Ventures. Wavemaker Partners has exited its stake, on undisclosed terms.
Compiled by commissioned research from 2 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 3
by search overlap
Companies competing with RxVantage for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline · 3
launches, deals, and filingsWavemaker Partners exited its stake in RxVantage; financial terms were not disclosed.
RxVantage announced a new investment led by Spectrum Equity and McKesson Ventures, joining existing investors dRx Capital (Novartis), Merck Global Health Innovation Fund, Javelin Venture Partners and Slater Technology Fund. Amount not disclosed.
RxVantage added staff organically and via the acquisition of onPoint oncology during 2021.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 2
primary sources listed
- RxVantage, Inc. Asset Profile | Preqinpreqin.com · web
2 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does RxVantage do?
- RxVantage runs a software and data platform that connects medical practices with life science experts and reps.
- Who are RxVantage's investors?
- RxVantage's investors include Javelin Venture Partners, McKesson Ventures, Slater Technology Fund, Spectrum Equity.